Shares of Stevanato Group S.p.A. (NYSE:STVN – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company.
Separately, Stephens reiterated an “overweight” rating and set a $38.00 price objective on shares of Stevanato Group in a research note on Monday, March 25th.
Check Out Our Latest Research Report on Stevanato Group
Hedge Funds Weigh In On Stevanato Group
Stevanato Group Stock Down 1.6 %
Shares of STVN opened at €28.40 ($30.21) on Friday. The stock’s fifty day moving average price is €30.64 and its two-hundred day moving average price is €29.58. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.06 and a current ratio of 1.50. Stevanato Group has a 1 year low of €23.00 ($24.47) and a 1 year high of €36.30 ($38.62).
Stevanato Group (NYSE:STVN – Get Free Report) last issued its earnings results on Thursday, March 7th. The company reported €0.18 ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of €0.19 ($0.20) by (€0.01) (($0.01)). Stevanato Group had a net margin of 13.43% and a return on equity of 14.31%. The firm had revenue of €320.60 million during the quarter, compared to the consensus estimate of €326.85 million. During the same quarter in the previous year, the firm earned $0.19 earnings per share. The business’s quarterly revenue was up 9.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Stevanato Group will post 0.67 earnings per share for the current year.
Stevanato Group Company Profile
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.
Featured Articles
- Five stocks we like better than Stevanato Group
- 3 Healthcare Dividend Stocks to Buy
- Comprehensive PepsiCo Stock Analysis
- 3 Tickers Leading a Meme Stock Revival
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- How to buy stock: A step-by-step guide for beginners
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.